Search
Arcutis Biotherapeutics Inc
ARQTAdd to Watchlist
25.960USD
+0.580+2.29%
Close 09-21 16:00（ET）
3.26BMarket Cap
LossP/E TTM
Arcutis Biotherapeutics Inc (ARQT) Stock Price Target & Forecast
Analyst Rating
Based on 8 analysts giving stock ratings to Arcutis Biotherapeutics Inc in the past month.
Buy
2 Strong Buy
5 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
37.000USD+45.78%
ARQT Analyst Recommendation Trends
In the current month, ARQT has received 5 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ARQT average Analyst price target in the last month is 37.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
2
2
2
2
2
2
2
2
5
5
5
5
5
5
5
5
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
8
8
8
8
8
8
8
ARQT Analyst Rating for Peer Comparison
Updated: Sep 21, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
7
17
12
1
0
37
Amgen Inc
AMGN
4
12
18
2
1
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Pfizer Inc
PFE
5
6
19
1
1
32
Regeneron Pharmaceuticals Inc
REGN
6
15
11
0
0
32
Merck & Co Inc
MRK
8
14
10
0
0
32
Vertex Pharmaceuticals Inc
VRTX
9
16
5
0
1
31
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Financial Forecasting
Based on analysts' estimates, ARQT EPS is projected to reach 0.172 in FY2026Q3, following reported EPS of 0.115 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
0.11
-0.08
0.04
0.17
0.24
Actual
0.14
-0.09
0.11
--
--
Surprise
+19.59%
-6.29%
+167.42%
--
--
FAQs
What is Arcutis Biotherapeutics Inc's expected revenue for the next quarter?
Arcutis Biotherapeutics Inc's expected revenue is 141.69M.
What is Arcutis Biotherapeutics Inc's price target?
Analysts forecast that Arcutis Biotherapeutics Inc's price target is USD 37.00, with the highest forecast at USD 40.00 and the lowest forecast at USD 34.00.
How have Arcutis Biotherapeutics IncARQT's recent earnings per share performed?
The market expectation was USD 0.11, while Arcutis Biotherapeutics IncARQT's earnings per share (EPS) for the previous quarter was USD -0.09. EPS for the next quarter is expected at USD 0.17.
What is the analyst rating for Arcutis Biotherapeutics Inc?
Based on the ratings of Arcutis Biotherapeutics Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.